THE ARISING · Markets & Strategy
Investors Say High Consumer Longevity Valuations Will Push the Sector Toward a Decade of M&A
Consumer longevity companies priced for rapid growth may have to buy their way there, according to investors who spoke at a recent industry panel.
Longevity.Technology reported on the discussion, held at INNOCOS Zurich and moderated by Zsolt Farkas of Evolut. According to the report, the panelists expect high valuations to drive aggressive acquisitions over the next decade.
The report cites Oura at a valuation of about $11 billion, with a roadshow target of more than $15 billion. It also cites Function Health, whose valuation rose from $191 million to $2.5 billion in 17 months, alongside a $450 million growth round.
Panelists said companies at those prices will likely need to acquire others to grow into them. According to the report, they expect firms to merge scattered products into integrated "health operating systems."
Nicholas Gnan of Peers Capital said value depends on the customer base. "It's the purchasing power of the customer that you can talk to that decides the value of the business," he said, according to the report.
Arnaud Autret of L'Oréal BOLD, a corporate venture unit, described why large companies buy. "It's more about buying time than buying specific assets," he said.
Max Gottschalk of The Longevity Fund pointed to a limit on marketing-led growth. "Marketing can buy you into a market, but not a second purchase," he said.
Panelists also warned that overstating the scientific evidence can end a company's appeal to potential acquirers, according to the report. For founders, that ties the credibility of their claims directly to their exit options.
The panel's views are forecasts from investors and a corporate executive, not outcomes. What to watch next: whether the high-valuation consumer firms start announcing acquisitions, and how buyers treat companies whose science claims run ahead of the evidence.
- Humana Wins and Alignment Threatens to Sue as 2027 Medicare Advantage Star Ratings Land 2. German Cabinet Approves Long-Term Care Insurance Reform, Raising Contributions for Childless Members and Higher Earners 3. Investors Say High Consumer Longevity Valuations Will Push the Sector Toward a Decade of M&A 4. Genentech Pays $100 Million Upfront for Alector's Brain-Penetrant Parkinson's Enzyme Therapy AL050 5. European Commission Official Warns EU Workforce Will Shrink by About One Million a Year by 2050